Product
Leflunomide
Aliases
Arava, SU101
22 clinical trials
34 indications
Indication
Multiple MyelomaIndication
Chronic Nonbacterial OsteomyelitisIndication
Smoldering Plasma Cell MyelomaIndication
RAS MutationIndication
Ras Gene MutationIndication
Colorectal Cancer RecurrentIndication
Pancreatic CancerIndication
lung cancerIndication
MelanomaIndication
Refractory CancerIndication
Healthy VolunteerIndication
COVID-19Indication
PTEN-null Advanced Solid TumorsIndication
Rheumatoid ArthritisIndication
Autoimmune DiseasesIndication
Recurrent Lymphoproliferative DisorderIndication
Refractory Lymphoproliferative DisorderIndication
Henoch-Schönlein purpuraIndication
Psoriatic ArthritisIndication
Idiopathic Pulmonary HemosiderosisIndication
LeflunomideIndication
MEN1 Gene MutationIndication
Acute Graft Versus Host DiseaseIndication
Breast NeoplasmsIndication
Breast DiseasesIndication
Triple Negative Breast CancerIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
Pancreatic AdenocarcinomaIndication
Stage III Pancreatic CancerIndication
Pancreatic Ductal AdenocarcinomaIndication
Sjögren's syndromeClinical trial
A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2018-09-18
Clinical trial
CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Pilot Trial of Leflunomide in Patients With High-Risk Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
New Therapeutic Approaches for Tumors With RAS Gene MutationsStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Single Dose, Randomized, Open-label, One-period Parallel Bioequivalence Study of Generic Leflunomide 20 mg Film-coated Tablets and Reference Product (Arava®) in Healthy Thai Male Volunteers Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-04-23
Clinical trial
Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19Status: Terminated, Estimated PCD: 2022-01-31
Clinical trial
A Phase IA/IB Trial of Leflunomide in Patients With PTEN-null Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid ArthritisStatus: Completed, Estimated PCD: 2010-03-11
Clinical trial
A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Efficacy of Mycophenolate Mofetil Versus Leflunomide as Maintenance Treatment for IgG4-RD Patients With Internal Organ InvolvementStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Trial of Leflunomide in Patients With CD30+ Lymphoproliferative DisordersStatus: Completed, Estimated PCD: 2021-07-28
Clinical trial
Leflunomide for Refractory Skin Henoch-Schonlein Purpura in ChildrenStatus: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial.Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Leflunomide is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis RemissionStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Leflunomide Treatment for MEN1 Patients - the LUMEN1 TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-05
Clinical trial
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative CancersStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome (pSS): an Interventional Trial Based on stratifYing PatientsStatus: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent MalignancyStatus: Terminated, Estimated PCD: 2023-06-18
Clinical trial
A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-11-13